Looking at such controversy, it can be suggested that implementation of more reliable surrogate for assessing systemic androgenecity, such as SHBG level, might be appropriate for the prediction of outcomes among PCa patients undergoing treatment. The gene discussed is SHBG; the disease is posterior cortical atrophy.